Université Grenoble Alpes

Centre Hospitalier Universitaire Grenoble

Centre Hospitalier Universitaire Grenoble Alpes

Establissement Francais Du Sang

Université Joseph Fourier - Grenoble 1

Audrey Le Gouellec

Bertrand Toussaint

Philippe Cinquin

Donald Keith Martin

Abdelkader Zebda

Jean-Pierre Alcaraz

Jacques Thelu

Patrick Tuvignon

Dominique Schneider

Sarra El Ichi

Max Maurin

Benoît Polack

Fabian Reche

Elodie Meynet

David Laurin

Jean-Luc Lenormand

Sarra El Ichi Ribault

The present disclosure is related to a live-attenuated strain offor its use as a vaccine, and for use in a method for preventive immunizing and for treatinginfection, in particular in patients suffering from cystic fibrosis. Preferably, the live-attenuated strain ofis furthermore treated to become 'killed but metabolically active'.

Attenuated strain of pseudomonas as a vaccine for pseudomonas infection

The device, that can be implanted in the intestinal cavity, comprises a reactor comprising a semi-permeable or porous membrane or coating linked to a element for attachment to an intestinal or gastric wall. The reactor can be in the form of a ribbon, a structure having more than two faces or an open structure delimiting a lumen, comprising, or formed from, a semi-permeable or porous membrane. The reactor can also delimit, at least partially with the semi-permeable or porous membrane of same, a closed inner space. The reactor can comprise or carry enzymes or micro-organisms, in particular bacteria or yeast. The reactor is used for generating a chemical reaction with one or more molecules present in the intestine, or for producing one or more biologically active molecules. It can, in particular, be used for consuming sugars, disaccharides and simple sugars or producing essential amino acids or other molecules having a positive effect on the health.

Implantable intestinal reactor

A process for obtaining an adapted strain ofincludes the following steps: deleting the genes ExoS, ExoT, aroA and IasI in an initialstrain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become 'killed but metabolically active'.

Attenuated and adapted strain of pseudomonas for delivering antigens

Growing community of inventors

Uriage, France

Audrey Le Gouellec